Previous 10 | Next 10 |
Summary Avid Bioservices is primed to more than double capacity over the next few quarters. Perception should change as Avid fills its new capacity and develops into a free cash flow machine. It would not surprise me to see fast growing, recession resistant cash flows valued at 20x,...
Summary Laughing Water Capital is a concentrated, long-biased investment partnership open to accredited investors. For the fourth quarter of 2022, an investment in Class A shares of Laughing Water Capital, net of all fees and expenses, returned approximately 4.0% vs 7.6% and 6.2% ...
HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024 PR Newswire SAN DIEGO , Jan. 11, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it has elected to redeem on March...
Halozyme Therapeutics ( NASDAQ: HALO ) on Tuesday said it expected 2023 total revenue of $815M to $845M, significantly below the consensus revenue estimate of $892.43M. Shares of the San Diego, Calif.-based company fell 7.3% to $51.61 after hours. HALO said it expects 2023...
Halozyme Provides 2023 Financial Guidance and Outlook PR Newswire 2023 Total Revenue Guidance of $815 to $845 Million Representing >20% Growth Over Expected 2022 Revenue 2023 Recurring Revenues from Royalties Projected to Grow by >20% to $445 to $...
Summary The stock of Halozyme Therapeutics, Inc. has moved up nicely in recent months, buoyed by solid third quarter results and positive commentary from the analyst firm community. However, Halozyme stock is hitting up against some price targets and insiders have notably started to sel...
Summary BMEZ’s portfolio has a combination of unknown small-cap "next generation" healthcare holdings and some familiar names in the field of biotechnology. Lack of diversification makes BMEZ susceptible to sector-specific risk. It also has a relatively high expense ratio despite...
Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO , Jan. 3, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief executive officer...
Summary Smallcaps are the first ones to get affected by the recession and the last ones to show recovery. Key fundamental drivers of the VTWO ETF are rising interest rates, recession, and overall bearish sentiments of the markets. My technical analysis framework based on Trend Flow,...
Morgan Stanley has initiated Halozyme Therapeutics ( NASDAQ: HALO ) at overweight citing the company's Enhanze technology used for subcutaneous administration of therapies that is licensed to companies. The firm has a $65 price target (~15% upside based on Tuesday's close). Analys...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...